Abstract: A trailer brake module includes a brake output driver configured to be connected to a power supply, a flyback diode, and a MOSFET arranged between the power supply and the flyback diode. The MOSFET is in series with the flyback diode.

Abstract: A trailer brake module includes a brake output driver configured to be connected to a power supply, a flyback diode, and a MOSFET arranged between the power supply and the flyback diode. The MOSFET is in series with the flyback diode.

Abstract: A circuit may be configured to adjust a correction signal for each phase of an electric motor based on a rotational position of a spindle of the electric motor, generate a distorted waveform based on the correction signal, and drive the electric motor in response to the distorted waveform. In some examples, back electromotive force (BEMF) may be determined in order to adjust a motor drive waveform, which may reduce or eliminate motor vibrations. A motor drive signal may be pre-warped (i.e. distorted) such that when the correctional signal and drive signals are combined, there is a reduction in acoustic emissions or motor vibrations. Other parameters, such as cogging torque, may be measured to reduce motor vibration and acoustic emissions.

Abstract: A circuit may be configured to adjust a correction signal for each phase of an electric motor based on a rotational position of a spindle of the electric motor, generate a distorted waveform based on the correction signal, and drive the electric motor in response to the distorted waveform. In some examples, back electromotive force (BEMF) may be determined in order to adjust a motor drive waveform, which may reduce or eliminate motor vibrations. A motor drive signal may be pre-warped (i.e. distorted) such that when the correctional signal and drive signals are combined, there is a reduction in acoustic emissions or motor vibrations. Other parameters, such as cogging torque, may be measured to reduce motor vibration and acoustic emissions.

Abstract: Disclosed is a method of treating a subject with cancer, the method comprising the step of co-administering to the subject over three to five weeks, a taxane in an amount of between about 243 ?mol/m2 to 315 ?mol/m2; and a bis(thiohydrazide amide) compound in an amount between about 1473 ?mol/m2 and about 1722 ?mol/m2.

Abstract: A method of treating a subject with cancer includes the step of co-administering to the subject over three to five weeks, a taxane in an amount of between about 243 ?mol/m2 to 315 ?mol/m2 (e.g., equivalent to paclitaxel in about 210-270 mg/m2); and a bis(thiohydrazide amide) in an amount between about 1473 ?mol/m2 and about 1722 ?mol/m2 (e.g., Compound (1) in about 590-690 mg/m2). The bis(thiohydrazide amide) is represented by Structural Formula (I), Y is a covalent bond or an optionally substituted straight chained hydrocarbyl group, or, Y, taken together with both >C=Z groups to which it is bonded, is an optionally substituted aromatic group. R1-R4 are independently —H, an optionally substituted aliphatic group, an optionally substituted aryl group, or R1 and R3 taken together with the carbon and nitrogen atoms to which they are bonded, and/or R2 and R4 taken together with the carbon and nitrogen atoms to which they are bonded, form a non-aromatic heterocyclic ring optionally fused to an aromatic ring.

Abstract: Various embodiments relate to selectively inhibiting output from a transducer in response to the rate of change of acceleration that is experienced by the transducer. The rate of change of an acceleration signal, which is indicative of transducer's acceleration, is detected. Output of a signal through the transducer is selectively inhibited in response to the detected rate of change of the acceleration signal. A related apparatus can include a circuit that detects the rate of change of an acceleration signal and generates a transducer output inhibit signal in response to the detected rate of change of the acceleration signal. The transducer writes data on a recordable media. The accelerometer generates an acceleration signal that is indicative of transducer vibration. The circuit selectively inhibits writing of data through the transducer in response to a rate of change of the acceleration signal.

Abstract: Various embodiments relate to selectively inhibiting output from a transducer in response to the rate of change of acceleration that is experienced by the transducer. The rate of change of an acceleration signal, which is indicative of transducer's acceleration, is detected. Output of a signal through the transducer is selectively inhibited in response to the detected rate of change of the acceleration signal. A related apparatus can include a circuit that detects the rate of change of an acceleration signal and generates a transducer output inhibit signal in response to the detected rate of change of the acceleration signal. Another related apparatus can include a transducer, an accelerometer, and a circuit. The transducer writes data on a recordable media. The accelerometer generates an acceleration signal that is indicative of transducer vibration. The circuit selectively inhibits writing of data through the transducer in response to a rate of change of the acceleration signal.

Abstract: Disclosed herein are methods of treating lentigo maligna, superficial spreading malignant melanoma, acral lentiginous malignant melanoma or nodular malignant melanoma with bis(thio-hydrazide amides) represented by a formula selected from structural formulas (i)-(ix) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these bis(thio-hydrazide amides) and compositions comprising these bis(thiohydrazide)amides and one or more anti-cancer agent.

Abstract: Disclosed herein are methods of preventing or delaying the recurrence of melanoma in a subject with bis(thio-hydrazide amides) represented by a formula selected from Structural Formulas (I)-(IX) or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising these bis(thio-hydrazide amides) and compositions comprising these bis(thiohydrazide)amides and one or more anti-cancer agent.